CAS
LXRX icon

Coppell Advisory Solutions’s Lexicon Pharmaceuticals LXRX Stock Holding History

Coppell Advisory Solutions’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-52
Closed -$37 – 1206
2024
Q4 		$37 Hold
52
– – ﹤0.01% 1945
2024
Q3 		$83 Hold
52
– – ﹤0.01% 1807
2024
Q2 		$87 Buy
+52
New +$93 ﹤0.01% 1725
2023
Q4 		$80 Sell
52
-61
-54% -$73 ﹤0.01% 1658
2023
Q3 		$216 Buy
113
+61
+117% +$107 ﹤0.01% 1107
2023
Q2 		$113 Buy
+52
New +$138 ﹤0.01% 1371
2023
Q1 		– Sell
-113
Closed -$216 – 704
2022
Q4 		$216 Buy
+113
New +$240 ﹤0.01% 1108

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CIBC Private Wealth Group
CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Coppell Advisory Solutions's LXRX Position: Q1 2025 in Review

Coppell Advisory Solutions sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2025, closing a stake of 52 shares — an estimated $37 sold.

Coppell Advisory Solutions first reported a position in LXRX in Q4 2022 and held it in 7 quarters. The position peaked at $216 in Q3 2023. 127 funds tracked by Wall St. Rank hold LXRX as of Q1 2025.

  • Coppell Advisory Solutions reported no remaining Lexicon Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Coppell Advisory Solutions sold 52 Lexicon Pharmaceuticals shares in Q1 2025, an estimated $37.
  • Coppell Advisory Solutions first reported a position in Lexicon Pharmaceuticals in Q4 2022 and held it in 7 quarters.
  • Coppell Advisory Solutions's Lexicon Pharmaceuticals position peaked at $216 in Q3 2023.
  • 127 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2025.

Based on Coppell Advisory Solutions's 13F filing for Q1 2025, filed 16 May 2025.